EPHA2 and cancer: In a single other study of a nascent lung metastasis model, consistent with the studies herein, Kakarla et al. 16 found that combining FAP-specific T cells with T cells that targeted the EphA2 antigen on A549 cancer cells, enhanced overall anti-tumor activity and conferred a survival advantage compared to either alone.